PTO/SB/08x (08-03.)
Approved for use through 07/31/2006. ONB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Us remained research Reduction Act of 1995, no persons are required to responsible control or transmission of the control of the Publication Number

| Application Number | 10535350

	Application Number	10535360	
NEODMATION DIOOLOGUDE	Filing Date	2005-10-06	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor He	nry Petersen	
Not for submission under 37 CFR 1.99)	Art Unit	3679	
not for submission and or or it is any	Examiner Name		
	Attorney Docket Number	A5-1952	

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines wh ant Passages or Re es Appear	
	1	6006788		1999-1	2-28	Jung, et al				
If you wisl	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d buttor	n. Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code4		Name of Patente Applicant of cited Document	e or	Pages,Columns,Lir where Relevant Passages or Relev Figures Appear	74
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
			NON	-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Ts					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10535360	
	Filing Date		2005-10-06	
	First Named Inventor Henry		y Petersen	
	Art Unit		3679	
(Not for Submission ander or or it issay	Examiner Name			
	Attorney Docket Number		A5-1952	

		1		_			
	If you wish	n to a	dd additional non-patent literature document citation information please click the Add button Add				
ı	FYAMINER SIGNATURE						

Examiner Signature | Date Considered |
"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See You Code of USPTO Pears Documents at your USPTO_EGY or NEEP 910.4. I fetter office that issued the document by the two-lefter code (NIPO) Standard 67.3. I Free Uspanies patient documents, the solication of the year of the higher of the Emperor must preced the sental number of the patient document. Your of document by the appropriate across the solication on the document under WFD Standard 97.14 if pression. "Applicate is to place a cross many English terripoles president in a standard."

E T 9)	Application Number		10535360
	Filing Date		2005-10-06
	First Named Inventor	Henr	y Petersen
	Art Unit		3679
	Examiner Name		
	Attorney Docket Number		A5-1952

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

INFORMATION DISCLOSUR STATEMENT BY APPLICAN (Not for submission under 37 CFR 19

	That each item of information contained in the information disclosure statement was first cited in any communication
V	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information disclosure statement

OR

I hat no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Domenica N.S. Hartman/	Date (YYYY-MM-DD)	2006-03-04				
Name/Print	Domenica N.S. Hartman	Registration Number	32701				

This collection of information is required by 37 CFR. 187 and 1.98. The information is required to obtain or retain a benefit by the public which is to lie (and by the USFTO to process) an application. Confidentially is generate by \$5.U.S. CI. 20 and 37 CFR. 114. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. O. Box 1450, Alexandrin, V.S. 2231-1450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.A. 2231-3450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission, which may related the process another examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CPR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.